Skip to main content

Table 3 Estimated prevalence of CHC and CHB according to socio-demographical characteristics and risk exposure factors in the general population aged 18-75 years, BaroTest, mainland France, 2016

From: HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy

Characteristics Chronic hepatitis Ca (n = 6,931) Chronic hepatitis Bb (n = 6,945)
wBT% 95%CI p wBT% 95%CI p
Total   0.30 0.13-0.70   0.30 0.13-0.70  
Gender Men 0.34 0.14-0.84 NS 0.28 0.12-0.63 NS
Women 0.26 0.05-1.21 0.32 0.08-1.28
Age (in years) 18-45 0.08 0.01-0.45 < 0.05 0.10 0.03-0.29 < 0.05
46-75 0.51 0.20-1.32 0.51 0.19-1.34  
Educational level < secondary school certificate 0.52 0.19-1.37 < 10 −2 0.18 0.06-0.53 NS
≥ secondary school certificate 0.08 0.03-0.22 0.19 0.10-0.38
Household monthly income 1st tercile (low) 0.74 0.27-1.96 < 10 −3 0.63 0.20-1.96 < 0.05
2nd/3rd tercile 0.07 0.03-019   0.14 0.07-0.27  
Place of residence Ile-de-France (Paris region) 0.31 0.05-1.79 NS 0.16 0.04-0.60 NS
Other regions 0.30 0.11-0.78 0.34 0.13-0.84
Place of birth Mainland France 0.35 0.15-0.82   0.14 0.08-0.26 < 10 −3
French Overseas administrative areas 0    0   
Europe 0    0.96 0.13-6.48  
Maghreb 0    0   
Sub-Saharan Africa 0    5.81 0.95-28.5  
Other countries 0    0.73 0.10-5.10  
Health Insurance coverage for low-income personsc Yes 0.66 0.09-4.5 NS 1.98 0.43-8.59 < 10 −3
No 0.27 0.10-0.69 0.16 0.09-0.28  
Drug use during lifetime Yes, intravenous use with or without nasal use 12.1 2.93-38.4 < 10 −3 0   NS
Yes, nasal use only 0    0.24 0.03-1.71
No 0.24 0.09-0.67   0.31 0.13-0.74
Blood transfusion before 1992 Yes 1.12 0.24-5.03 NS    NS
No 0.24 0.09-0.67   
Healthcare or stays ≥3 months in Africa, Asia or Middle East Yes 0.33 0.06-1.85 NS 0.95 0.14-6.01 NS
No 0.29 0.11-0.76 0.21 0.11-0.40
Tattooing or piercing without single-use materials Yes 2.55 0.36-15.9 < 10 −2 0.9 0.10-6.17 NS
No 0.25 0.10-0.64 0.29 0.12-0.70
Lived with or sexual intercourse with an HBV infected person Yes    NS 0.68 0.20-2.34 NS
No    0.28 0.11-0.72
Sex with other men during lifetimed Yes 0.31 0.04-2.19 NS 3.39 0.84-12.7 < 10 −3
No 0.34 0.14-0.87 0.16 0.06-0.39  
Sexually transmitted infection(s) in the previous 12 monthse Yes 0.46 0.06-3.22 NS 1.16 0.16-7.82 NS
No 0.3 0.13-0.72   0.30 0.12-0.72  
HBV vaccination Yes 0.17 0.05-0.58 NS 0.36 0.09-1.39 NS
No 0.47 0.16-1.38 0.29 0.13-0.63
  1. wBT% BaroTest weighted percentage, aPR adjusted prevalence ratio, 95% CI 95% confidence interval, NS Not significant
  2. aDefined as positive HCV RNA
  3. bDefined as positive HBs Ag
  4. cIncludes Complementary Universal Health Insurance (CMU, which is free insurance for low-income persons) and State Medical Assistance (AME, which is free insurance for low-income irregular migrants)
  5. dAmong men who reported having had sexual relations in their lifetime (with men or women)
  6. eAmong individuals who have already had sexual relations. Mycosis are excluded
  7. The distributions are significantly different for numbers in bold